Global private equity healthcare specialist ARCHIMED further expands its presence in the Consumer Health sector with the acquisition of Groupe Laboratoire Rivadis.

After more than 50 years developing, manufacturing, and distributing skincare products, Groupe Laboratoire Rivadis (Rivadis) has longstanding medical credibility, gained through decades of serving hospitals, maternity clinics and other healthcare institutions. The company has developed a large product range intended for fragile populations, notably serving infants and the elderly, under the Rivadouce and Milton brands. The company also owns Auriège, a leading French cosmetics brand specialized in direct retail sales.

ARCHIMED’s Consumer Health team sourced the family-owned Rivadis investment opportunity directly, after a deep dive into the dermo-cosmetics sector (products serving both cosmetic and dermatological needs). The sector is a priority investment area for ARCHIMED, singled out using MedSeg, the group’s sector analysis tool. Rivadis was then screened by ARCHIMED’s Consumer Health team and identified as a particularly promising company through ARCHIMED’s proprietary MedDiscover approach.

“Rivadis has industry-leading medical expertise, a robust R&D operation, significant production capacity and an intimate knowledge of its distribution networks,” says Jean-Yves Desmottes, partner at ARCHIMED. “Rivadis’ strong ESG commitment and its products designed for fragile skin [such as for babies or the elderly where risks of infection and irritation are high] dovetail perfectly with ARCHIMED’s goal of improving patient outcomes.”

ARCHIMED can invest from €10 million to €1 billion per investment through its different fund lines. All fully deployed ARCHIMED funds have top decile performance, especially from a DPI perspective (Source: PitchBook).